Literature DB >> 6506133

Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children.

B F Bourgeois, N Wad.   

Abstract

Steady-state levels of carbamazepine (CBZ), CBZ-10,11-epoxide (CBZ-E), and 10,11-dihydro-10,11-trans-dihydroxy-CBZ (CBZ-diol) were monitored in 53 adults and 16 children, and 24-h urinary excretion of CBZ-E and CBZ-diol was measured in 25 adults and 8 children. The CBZ dose correlated significantly with the serum level of the metabolites but not with the CBZ level. The variability of the CBZ dose/level ratio was related to comedication. Similarly, comedication altered the serum CBZ-diol/CBZ ratio and, to a lesser extent, the CBZ-E/CBZ as well as the CBZ-diol/CBZ-E ratios. Fluctuations of the CBZ-diol levels during the day were less than half as high as CBZ fluctuations. Children had a higher CBZ dose/level ratio and a relatively lower serum CBZ-diol/CBZ ratio, possibly because they also had a higher renal clearance for CBZ-diol. The fraction of the CBZ dose excreted as urinary CBZ-diol was equal in adults and children (35.2 and 36.2%, respectively). The results of this study suggest that the steady-state serum CBZ-diol/CBZ ratio is a sensitive indicator of enzymatic induction and that it can be useful in determining if unexpected CBZ levels can be attributed to the rate of enzymatic conversion of CBZ.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6506133     DOI: 10.1097/00007691-198409000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  16 in total

1.  Population characteristics of biological systems influenced by multicomponent random and uniform variation.

Authors:  G M Kochak
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

Review 2.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 3.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 4.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

5.  Early stage autoinduction of carbamazepine metabolism in humans.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

7.  Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Procaccianti; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

9.  Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide.

Authors:  R P Remmel; M W Sinz; J C Cloyd
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

Review 10.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.